ZUERBLIS KENNETH J 4
4 · SAVIENT PHARMACEUTICALS INC · Filed Feb 13, 2012
Insider Transaction Report
Form 4
ZUERBLIS KENNETH J
EVP, Chief Financial Officer
Transactions
- Award
Option to Purchase Common Stock, $.01 par value
2012-02-01$2.26/sh+100,000$226,000→ 100,000 totalExercise: $2.26From: 2013-02-01Exp: 2022-02-01→ Common Stock, $.01 par value per share (100,000 underlying)
Footnotes (1)
- [F1]These options vest as to one-third on each of the first three anniversaries of the grant date, provided that the grantee remains employed by the Company on these dates.